PositoAI/ US/ MBX Biosciences, Inc.

MBX Biosciences, Inc.

NasdaqGS: MBX · Healthcare

Positivity Index

#5,299 / 6,775

Global

#2,844 / 4,000

United States

Positivity Score

17,896

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

MBX Biosciences, Inc. — Overview & Financial Snapshot

MBX Biosciences, Inc. (NasdaqGS: MBX) is a Healthcare company, ranked #5,299 of 6,775 companies globally and #2,844 of 4,000 in United States on PositoAI, with a Positivity Score of 17,896. Its market capitalisation is ₹22,138.89 Cr ($2.34B), P/E ratio is -20.5 and P/B ratio is 5.70. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

P/B Ratio 5.70

P/E Ratio -20.5

D/E Ratio 0.01

ROE -33.17%

Owes vs Owns ? 0.06× Low $0.06 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-224.63$-2.37

Forward EPS ₹-376.83$-3.98

Beta 0.10

Market Cap ₹22,138.89 Cr$2.34B

What these numbers mean →

What does MBX Biosciences, Inc. do?

What is MBX Biosciences, Inc.'s P/E and P/B ratio?

MBX Biosciences, Inc. has a P/E ratio of -20.5 and a P/B ratio of 5.70.

What is MBX Biosciences, Inc.'s debt-to-equity ratio?

MBX Biosciences, Inc. has a debt-to-equity ratio of 0.01.

How much does MBX Biosciences, Inc. owe compared with what it owns?

MBX Biosciences, Inc. owes $0.06 for every $1 it owns (balance sheet Jun 2026), which is low.

What is MBX Biosciences, Inc.'s Positivity rank?

MBX Biosciences, Inc. is ranked #5,299 of 6,775 companies globally and #2,844 of 4,000 in United States on PositoAI, with a Positivity Score of 17,896.

Does MBX Biosciences, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for MBX Biosciences, Inc..

Where can I read the latest news about MBX Biosciences, Inc.?

Recent headlines about MBX Biosciences, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does MBX Biosciences, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of MBX Biosciences, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.